Macquarie Group’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $492K | Sell |
2,168
-199,455
| -99% | -$35.5M | ﹤0.01% | 722 |
|
|
2026
Q1 | $34.8M | Sell |
201,623
-518
| -0.3% | -$96K | 0.21% | 92 |
|
|
2025
Q4 | $40.3M | Sell |
202,141
-27,950
| -12% | -$5.07M | 0.18% | 104 |
|
|
2025
Q3 | $36M | Buy |
230,091
+227,433
| +8,557% | +$36.1M | 0.04% | 510 |
|
|
2025
Q2 | $403K | Sell |
2,658
-48,926
| -95% | -$6.52M | ﹤0.01% | 1485 |
|
|
2025
Q1 | $7.76M | Buy |
51,584
+9,923
| +24% | +$1.66M | 0.01% | 862 |
|
|
2024
Q4 | $7.33M | Buy |
41,661
+38,250
| +1,121% | +$7.37M | 0.01% | 866 |
|
|
2024
Q3 | $672K | Buy |
3,411
+1,100
| +48% | +$229K | ﹤0.01% | 1438 |
|
|
2024
Q2 | $477K | Sell |
2,311
-32,324
| -93% | -$7.32M | ﹤0.01% | 1469 |
|
|
2024
Q1 | $9.38M | Buy |
34,635
+6,135
| +22% | +$1.47M | 0.01% | 842 |
|
|
2023
Q4 | $6.74M | Buy |
28,500
+13,214
| +86% | +$2.6M | 0.01% | 904 |
|
|
2023
Q3 | $3M | Sell |
15,286
-595
| -4% | -$122K | ﹤0.01% | 1054 |
|
|
2023
Q2 | $3.34M | Sell |
15,881
-5,555
| -26% | -$1.11M | ﹤0.01% | 1026 |
|
|
2023
Q1 | $4.33M | Buy |
21,436
+14,508
| +209% | +$3.29M | 0.01% | 960 |
|
|
2022
Q4 | $1.51M | Sell |
6,928
-3,652
| -35% | -$798K | ﹤0.01% | 1295 |
|
|
2022
Q3 | $2.08M | Buy |
10,580
+4,853
| +85% | +$1.05M | ﹤0.01% | 1212 |
|
|
2022
Q2 | $1.23M | Buy |
5,727
+4,513
| +372% | +$1.1M | ﹤0.01% | 1438 |
|
|
2022
Q1 | $345K | Sell |
1,214
-96
| -7% | -$29.6K | ﹤0.01% | 1728 |
|
|
2021
Q4 | $493K | Sell |
1,310
-748
| -36% | -$291K | ﹤0.01% | 1654 |
|
|
2021
Q3 | $849K | Sell |
2,058
-339
| -14% | -$141K | ﹤0.01% | 1624 |
|
|
2021
Q2 | $887K | Buy |
2,397
+617
| +35% | +$206K | ﹤0.01% | 1620 |
|
|
2021
Q1 | $515K | Sell |
1,780
-495
| -22% | -$138K | ﹤0.01% | 1529 |
|
|
2020
Q4 | $568K | Buy |
2,275
+158
| +7% | +$37.6K | ﹤0.01% | 1431 |
|
|
2020
Q3 | $479K | Buy |
2,117
+100
| +5% | +$20.8K | ﹤0.01% | 1413 |
|
|
2020
Q2 | $352K | Buy |
2,017
+698
| +53% | +$111K | ﹤0.01% | 1424 |
|
|
2020
Q1 | $166K | Hold |
1,319
| – | – | ﹤0.01% | 1501 |
|
|
2019
Q4 | $201K | Sell |
1,319
-1,740
| -57% | -$241K | ﹤0.01% | 1605 |
|
|
2019
Q3 | $405K | Sell |
3,059
-726
| -19% | -$97.3K | ﹤0.01% | 1412 |
|
|
2019
Q2 | $538K | Buy |
3,785
+2,617
| +224% | +$355K | ﹤0.01% | 1340 |
|
|
2019
Q1 | $170K | Buy |
1,168
+1,068
| +1,068% | +$140K | ﹤0.01% | 1476 |
|
|
2018
Q4 | $11K | Buy |
+100
| New | +$12.5K | ﹤0.01% | 1904 |
|
|
2018
Q3 | – | Sell |
-400
| Closed | -$45K | – | 2173 |
|
|
2018
Q2 | $45K | Buy |
+400
| New | +$43.2K | ﹤0.01% | 1962 |
|
Other funds holding CRL
AI
Macquarie Group's CRL Position: Q2 2026 in Review
Macquarie Group reduced its Charles River Laboratories (CRL) stake by 99% in Q2 2026, selling an estimated $35.5M and leaving 2,168 shares worth $492K. The position accounts for ﹤0.01% of the portfolio, ranked #722.
Macquarie Group first reported a position in CRL in Q2 2018 and has held it in 32 quarters since. The position peaked at $40.3M in Q4 2025. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Macquarie Group held 2,168 shares of Charles River Laboratories worth $492K as of Q2 2026.
- Macquarie Group sold 199,455 Charles River Laboratories shares in Q2 2026, an estimated $35.5M.
- Charles River Laboratories made up ﹤0.01% of Macquarie Group's portfolio in Q2 2026, its #722 holding.
- Macquarie Group first reported a position in Charles River Laboratories in Q2 2018 and has held it in 32 quarters since.
- Macquarie Group's Charles River Laboratories position peaked at $40.3M in Q4 2025.
- 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.